RadNet reported a 22.1% revenue increase to $575.6 million in Q1 2026, driven by a 19.7% rise in advanced imaging volumes and a 51.5% jump in digital health revenue. Despite a loss per share of $0.28 adjusted for one-time items, the company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and free cash flow due to strong operational momentum. RadNet also expanded its digital health capabilities with the acquisition of Gleamer SAS and launched a joint venture with Trinity Health’s Saint Alphonsus Health System, signaling growth in AI-powered radiology solutions and outpatient imaging services.
Sitryx Therapeutics, a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, announced its management will participate in three key investor conferences in June 2026: Jefferies Global Healthcare Conference in New Y...
Regeneron Pharmaceuticals' stock fell over 10% following the Phase 3 trial results for their melanoma treatment combining fianlimab and cemiplimab. The trial did not achieve statistical significance for the primary endpoint of progression-free surviv...
Auddia Inc. spotlighted the AI infrastructure opportunity of its LT350 subsidiary, referencing a $1.25 billion GPU cloud contract by SharonAI as a market benchmark. LT350's patented design uses parking lot airspace to deploy up to 960,000 GPUs, poten...
China Automotive Systems has begun volume shipments of its electric power steering (EPS) systems to a global automaker's European division. This marks a significant milestone as the EPS models will be used in two new vehicle models in Europe, with an...
Heineken N.V. has repurchased 2,543,263 shares under the second €750 million tranche of its €1.5 billion share buyback program as of May 15, 2026. The shares were bought both on the exchange and from Heineken Holding N.V., with an average price of €6...
